MCI-225

N/A

Report date: 2022/11/25 17:43:49
NME

Base Information

Drug NameMCI-225
Drug Alias NameAA-10025AA-10021MCI-225AA-10026DDP-225
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNorepinephrine reuptake inhibitorsSerotonin 3 (5-HT3) receptor antagonistsSerotonin reuptake inhibitors
TargetsSerotonin transporterNorepinephrine transporterSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsVomitingIrritable Bowel Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDynogen Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsVomitingIrritable Bowel Syndrome

Other Information

ATC CodeN/A
Related LinksN/A